Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exelixis, in collaboration with Merck Sharp & Dohme LLC, is conducting a clinical study titled A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C. The study aims to assess the safety and efficacy of experimental drug combinations in patients with clear cell renal cell carcinoma (ccRCC) who have experienced recurrence during or after anti-PD-(L)1 therapy. This research is significant as it explores new treatment avenues for a challenging cancer type.
The study is testing two combinations of drugs: Zanzalintinib and Belzutifan. These are oral tablets designed to be taken daily by participants until disease progression or treatment discontinuation. The goal is to find a safe and effective treatment regimen for ccRCC patients.
The study follows a non-randomized, parallel intervention model with a single-masked design, focusing primarily on treatment. It includes a safety lead-in phase to ensure the treatment’s tolerability before moving to the efficacy phase.
The study began on July 20, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 31, 2025, indicating ongoing recruitment and progress.
This study update could influence Exelixis’s stock performance positively if the results show promising outcomes, given the competitive landscape in cancer treatment. Investors should watch for further developments as they could impact market dynamics and investor sentiment.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.